Reviewer’s report

**Title:** A Greek registry of current Type 2 Diabetes Management, aiming to determine core clinical approaches, patterns and strategies

**Version:** 0  **Date:** 20 Mar 2018

**Reviewer:** Petros Thomakos

**Reviewer's report:**

The paper provides valuable data regarding glycaemic control in Greek Type-2 Diabetes Mellitus patients in relation to their therapeutic regimens.

The study was well conducted but there are several points that need to be addressed:

1) Page 5 line 3: "Glycaemic control expressed as 130mg/dl>FPG>70mg/dl at current visit" needs to be referenced

2) It should be mentioned that Metformin monotherapy should be started at diagnosis of Type-2 Diabetes along with Lifestyle modifications

3) The data in the results tables are described a second time in the text of the results

4) A separate analysis comparing glycaemic control between patients on insulin treatment (Group C) and those taking >2 antidiabetic agents could provide more useful information in relation to comparison between Group B (up to 3 antidiabetic agents)

5) The finding that "Patients on insulin therapy were older with longer diabetes duration" comparing to other Groups may be omitted from the abstract text since it does not add any valuable clinical information

6) It should be mentioned whether the diabetes complications were evaluated by the same way in all the centers

7) It is not clear whether HbA1c was measured using the same method by all the centers

**Are the methods appropriate and well described?**

If not, please specify what is required in your comments to the authors.

Yes
**Does the work include the necessary controls?**
If not, please specify which controls are required in your comments to the authors.

Unable to assess

**Are the conclusions drawn adequately supported by the data shown?**
If not, please explain in your comments to the authors.

Yes

**Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?**
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.
I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal